logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

HLS Therapeutics Inc.

HLS.TO

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIā€¦ read more

Healthcare

Drug Manufacturersā€”Specialty & Generic

5 years

CAD

Exclusive to Premium users

Price

per share adjusted in CAD

$5.08

Price

-0.30%

-$0.01

$5.09

Previous Close

$5.15

Open

Premium

52w Discount
Market Cap

$159.324m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$56.769m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$17.985m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.57

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$66.798m

$153.947m

Assets

$87.149m

Liabilities

$63.742m

Debt
Debt to Assets

41.4%

4.4x

Debt to EBITDA
Free Cash Flow

$10.734m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
ā†‘ TopSummaryPriceFinancials
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.